The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Open accessThe DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.
Abstract
Breast cancer affects approximately 1 in 8 women, and it is estimated that over 246,660 women in the USA will be diagnosed with breast cancer in 2016. Breast cancer mortality has decline over the last two decades due to early detection and improved treatment. Over the last few years, there is mounting evidence to demonstrate the prominent role of receptor tyrosine kinases (RTKs) in tumor initiation and progression, and targeted therapies against the RTKs have been developed, evaluated in clinical trials, and approved for many cancer types, including breast cancer. However, not all breast cancers are the same as evidenced by the multiple subtypes of the disease, with some more aggressive than others, showing differential treatment response to different types of drugs. Moreover, in addition to canonical signaling from the cell surface, many RTKs can be trafficked to various subcellular compartments, e.g., the multivesicular body and nucleus, where they carry out critical cellular functions, such as cell proliferation, DNA replication and repair, and therapeutic resistance. In this review, we provide a brief summary on the role of a selected number of RTKs in breast cancer and describe some mechanisms of resistance to targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Matteucci, E., Bendinelli, P., & Desiderio, M. A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp080 · Cited by 82
RetractedMapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Brand, T. M., Iida, M., Luthar, N., Wleklinski, M. J., Starr, M. M., & Wheeler, D. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071518 · Cited by 30
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“and is associated with poor clinical outcome and disease progression [89, 90].”
BackgroundLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 1×
“ERBB3-dependent activation of the PI3K pathway [158].”
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666 · cited 1×
“cell (CSC) phenotype in primary breast carcinoma via the Wnt/β-catenin signaling pathway, which is known for its role in CSC activity, such as self-renewal and migration [63].”
BackgroundUllrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
CA: A Cancer Journal for Clinicians
(2010) · CA A Cancer Journal for Clinicians · doi:10.3322/(issn)1542-4863 · Cited by 2,538
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · cited 1×
“In addition, combining immune checkpoint blockade with targeted therapies may boost efficacy and provide lasting effects against tumor cells [206, 207].”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“mechanisms have been shown to contribute to trastuzumab resistance, including constitutive activation of the downstream PI3Kpathwaydue inactivationor lossof tumor suppressorphosphatase and tensin homolog (PTEN) orPI3KCA genemutations [101, 102]; Src kinase activation conferred by PTEN deficiency [103]; overexpression…”
BackgroundThe landscape of cancer genes and mutational processes in breast cancer
The Oslo Breast Cancer Consortium (OSBREAC), Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-Zainal, S., Martin, S., Varela, I., et al. (2012) · Nature · doi:10.1038/nature11017 · Cited by 1,698
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9284 · Cited by 1,243
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Self-citationNuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Self-citationERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · cited 13×
“%) is responsible for acquired resistance to EGFR TKIs in patients with EGFR-mutated lung cancer by driving ERBB3-dependent activation of the PI3K pathway [158].”
BackgroundInfluentialDiverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956 · cited 6×
“Aberrant expression and mutations within the genes encoding the RTKs are well known to lead to the development of many diseases, including breast cancer [20, 21].”
BackgroundInfluentialKonecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913 · cited 3×
“Tumor suppressor phosphatase and tensin homolog (PTEN) reverses this process by dephosphorylating PIP3 [32] [33].”
BackgroundScaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Richard, J., Sainsbury, C., Needham, G., Farndon, J., Malcolm, A., & Harris, A. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90593-9 · Cited by 892
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · cited 1×
“Pertuzumab prevents dimerization of HER2 with other ERBB/HER receptors, particularly the most potent signaling heterodimer HER2/HER3 [95].”
BackgroundActivating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase
Ni, C.-Y., Murphy, M. P., Golde, T. E., & Carpenter, G. (2001) · Science · doi:10.1126/science.1065412 · Cited by 856
Role of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Harris, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00105-2 · Cited by 776
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Avraham, R., & Yarden, Y. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3048 · Cited by 672
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 595
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M. (2003) · The Journal of Pathology · doi:10.1002/path.1370 · Cited by 590
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., & Hung, M.-C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 544
Self-citationDittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515 · cited 1×
“mechanisms have been shown to contribute to trastuzumab resistance, including constitutive activation of the downstream PI3Kpathwaydue inactivationor lossof tumor suppressorphosphatase and tensin homolog (PTEN) orPI3KCA genemutations [101, 102]; Src kinase activation conferred by PTEN deficiency [103]; overexpression…”
BackgroundRitter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Wnt signaling: complexity at the surface
Cadigan, K. M., & Liu, Y. I. (2006) · Journal of Cell Science · doi:10.1242/jcs.02826 · Cited by 486 · cited 1×
“The extracellular region of Ryk contains a Wnt inhibitory factor-1 domain and has been reported to function as a receptor (or coreceptor) ofWnts, a large family of secreted glycoproteins that are involved in pattern formation, cell fate, axon guidance, neurite outgrowth, and tumor formation [194].”
BackgroundResensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Bergqvist, S., Brooun, A., Burke, B. J., Deng, Y.-L., Liu, W., Dardaei, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508887 · Cited by 484
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 471
Targeting the ERBB family in cancer: couples therapy
Tebbutt, N., Pedersen, M. W., & Johns, T. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3559 · Cited by 466
Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro
CARPENTER, G., KING, L., & COHEN, S. (1978) · Nature · doi:10.1038/276409a0 · Cited by 454
The epidermal growth factor receptor ligands at a glance
Schneider, M. R., & Wolf, E. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21635 · Cited by 447 · cited 6×
“, phosphatidylinositol 3-kinase (PI3K), Ras, phospholipase Cγ (PLCγ), and Janus-activated kinase (JAK) [21, 27].”
BackgroundInfluentialEGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts
Carpenter, G., Lembach, K., Morrison, M., & Cohen, S. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41417-8 · Cited by 435
A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai, K., Hung, M., & Yamaguchi, H. (2016) · Europe PMC (PubMed Central) · Cited by 421
Self-citationEGFR signal transactivation in cancer cells
Fischer, O. M., Hart, S., Gschwind, A., & Ullrich, A. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311203 · Cited by 411
Signal transduction by allosteric receptor oligomerization
Schlessinger, J. (1988) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(88)90219-8 · Cited by 399
Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases
Carraway III, K. L., Weber, J. L., Unger, M. J., Ledesma, J., Yu, N., Gassmann, M., & Lai, C. (1997) · Nature · doi:10.1038/387512a0 · Cited by 394
Liu, D., Ghiso, J. A. A., Estrada, Y., & Ossowski, L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00072-7 · Cited by 392
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Davies, K. D., & Doebele, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2851 · Cited by 373
The epidermal growth factor receptor variant III (EGFR v III): where wild things are altered
Gan, H. K., Cvrljevic, A. N., & Johns, T. G. (2013) · The FEBS Journal · doi:10.1111/febs.12393 · Cited by 370
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
Spatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3277 · Cited by 359
Bhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005) · Modern Pathology · doi:10.1038/modpathol.3800438 · Cited by 355
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Schlessinger, J. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008912 · Cited by 340
Tyrosine phosphorylation controls PCNA function through protein stability
Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Yang, C.-C., McIntush, E. W., Li, L.-Y., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Self-citationMolecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases
Waterman, H., & Yarden, Y. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02117-2 · Cited by 314
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.012 · Cited by 305
Self-citationExon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
Lin, E., Li, L., Guan, Y., Soriano, R., Rivers, C. S., Mohan, S., Pandita, A., Tang, J., & Modrusan, Z. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0522 · Cited by 302
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
Hanawa, M., Suzuki, S., Dobashi, Y., Yamane, T., Kono, K., Enomoto, N., & Ooi, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21454 · Cited by 298
STAT‐mediated EGFR signaling in cancer
Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21475 · Cited by 295
Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 290
Self-citationEGFR family: Structure physiology signalling and therapeutic targets †
Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802312844 · Cited by 288
Signaling on the endocytic pathway
von Zastrow, M., & Sorkin, A. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.04.021 · Cited by 280
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
Hirsch, F. R., Varella-Garcia, M., & Cappuzzo, F. (2009) · Oncogene · doi:10.1038/onc.2009.199 · Cited by 273
Lengyel, E., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K., Salanti, G., Richter, T., Knudsen, B., Vande Woude, G. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 273
Psyrri, A., Yu, Z., Weinberger, P. M., Sasaki, C., Haffty, B., Camp, R., Rimm, D., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 269
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
Reis‐Filho, J., Pinheiro, C., Lambros, M., Milanezi, F., Carvalho, S., Savage, K., Simpson, P., Jones, C., Swift, S., Mackay, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2004 · Cited by 266
Williams, C. C., Allison, J. G., Vidal, G. A., Burow, M. E., Beckman, B. S., Marrero, L., & Jones, F. E. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403155 · Cited by 263
Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4032 · Cited by 243
Self-citationThe type III epidermal growth factor receptor mutation
Pedersen, M. W., Meltorn, M., Damstrup, L., & Poulsen, H. S. (2001) · Annals of Oncology · doi:10.1023/a:1011177318162 · Cited by 241
Han, W., & Lo, H.-W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.011 · Cited by 240
(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00637-8 · Cited by 232
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
Ocana, A., Vera-Badillo, F., Seruga, B., Templeton, A., Pandiella, A., & Amir, E. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs501 · Cited by 225
Expression of c-met is a strong independent prognostic factor in breast carcinoma
Ghoussoub, R. A. D., Dillon, D. A., D'Aquila, T., Rimm, E. B., Fearon, E. R., & Rimm, D. L. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7 · Cited by 217
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
Rivera, E., & Gomez, H. (2010) · Breast Cancer Research · doi:10.1186/bcr2573 · Cited by 217
Prognostic value of ERBB family mRNA expression in breast carcinomas
Bièche, I., Onody, P., Tozlu, S., Driouch, K., Vidaud, M., & Lidereau, R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11273 · Cited by 214
Crosstalk in Met receptor oncogenesis
Lai, A. Z., Abella, J. V., & Park, M. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.07.002 · Cited by 213
Price‐Schiavi, S. A., Jepson, S., Li, P., Arango, M., Rudland, P. S., Yee, L., & Carraway, K. L. (2002) · International Journal of Cancer · doi:10.1002/ijc.10410 · Cited by 209
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Zhuang, G., Brantley-Sieders, D. M., Vaught, D., Yu, J., Xie, L., Wells, S., Jackson, D., Muraoka-Cook, R., Arteaga, C., & Chen, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1845 · Cited by 208
Offterdinger, M., Schöfer, C., Weipoltshammer, K., & Grunt, T. W. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109033 · Cited by 208
Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells
Aleksic, T., Chitnis, M. M., Perestenko, O. V., Gao, S., Thomas, P. H., Turner, G. D., Protheroe, A. S., Howarth, M., & Macaulay, V. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0052 · Cited by 205
Naresh, A., Long, W., Vidal, G. A., Wimley, W. C., Marrero, L., Sartor, C. I., Tovey, S., Cooke, T. G., Bartlett, J. M. S., & Jones, F. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2368 · Cited by 205
SnapShot: EGFR Signaling Pathway
Yarden, Y., & Shilo, B.-Z. (2007) · Cell · doi:10.1016/j.cell.2007.11.013 · Cited by 199
The clinical and functional significance of c-Met in breast cancer: a review
Ho-Yen, C. M., Jones, J. L., & Kermorgant, S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0547-6 · Cited by 197
Hung, L.-Y., Tseng, J. T., Lee, Y.-C., Xia, W., Wang, Y.-N., Wu, M.-L., Chuang, Y.-H., Lai, C.-H., & Chang, W.-C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn417 · Cited by 196
Wang, S.-C., & Hung, M.-C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2813 · Cited by 190
Self-citationHuang, W.-C., Chen, Y.-J., Li, L.-Y., Wei, Y.-L., Hsu, S.-C., Tsai, S.-L., Chiu, P.-C., Huang, W.-P., Wang, Y.-N., Chen, C.-H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240796 · Cited by 190
Self-citationOoi, A., Takehana, T., Li, X., Suzuki, S., Kunitomo, K., Iino, H., Fujii, H., Takeda, Y., & Dobashi, Y. (2004) · Modern Pathology · doi:10.1038/modpathol.3800137 · Cited by 187
Cleavable ErbB4 Isoform in Estrogen Receptor–Regulated Growth of Breast Cancer Cells
Junttila, T. T., Sundvall, M., Lundin, M., Lundin, J., Tanner, M., Härkönen, P., Joensuu, H., Isola, J., & Elenius, K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3150 · Cited by 187
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation
Farabaugh, S. M., Boone, D. N., & Lee, A. V. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00059 · Cited by 182
Wang, Y., & Hung, M. (2012) · Cell & Bioscience · doi:10.1186/2045-3701-2-13 · Cited by 170
Self-citationTeng, Y. H.-F., Tan, W.-J., Thike, A., Cheok, P. Y., Tse, G. M.-K., Wong, N.-S., Yip, G. W. C., Bay, B., & Tan, P. (2011) · Breast Cancer Research · doi:10.1186/bcr2857 · Cited by 165
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.
Srinivasan, R., Gillett, C., Barnes, D. M., & Gullick, W. J. (2000) · PubMed · Cited by 158
c-Met Must Translocate to the Nucleus to Initiate Calcium Signals
Gomes, D. A., Rodrigues, M. A., Leite, M. F., Gomez, M. V., Varnai, P., Balla, T., Bennett, A. M., & Nathanson, M. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706550200 · Cited by 156
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82826 · Cited by 155 · cited 1×
“EGFR mAb resistance in colorectal cancer [203].”
Self-citationXia, W., Wei, Y., Du, Y., Liu, J., Chang, B., Yu, Y., Huo, L., Miller, S. A., & Hung, M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20504 · Cited by 151
Self-citationBiological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
Pegram, M. D., & Slamon, D. (2000) · PubMed · Cited by 149
Hsp90 restrains ErbB‐2/HER2 signalling by limiting heterodimer formation
Citri, A., Gan, J., Mosesson, Y., Vereb, G., Szöllõsi, J., & Yarden, Y. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400300 · Cited by 149
Anaplastic lymphoma kinase in human cancer
Barreca, A., Lasorsa, E., Riera, L., Machiorlatti, R., Piva, R., Ponzoni, M., Kwee, I., Bertoni, F., Piccaluga, P. P., Pileri, S. A., et al. (2011) · Journal of Molecular Endocrinology · doi:10.1530/jme-11-0004 · Cited by 149
Cleavage of the Wnt Receptor Ryk Regulates Neuronal Differentiation during Cortical Neurogenesis
Lyu, J., Yamamoto, V. N., & Lu, W. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.10.004 · Cited by 148
Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 144
Expression and Nuclear Localization of ErbB3 in Prostate Cancer
Koumakpayi, I. H., Diallo, J.-S., Le Page, C., Lessard, L., Gleave, M., Bégin, L. R., Mes-Masson, A.-M., & Saad, F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2242 · Cited by 140
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
Sassen, A., Rochon, J., Wild, P., Hartmann, A., Hofstaedter, F., Schwarz, S., & Brockhoff, G. (2008) · Breast Cancer Research · doi:10.1186/bcr1843 · Cited by 139
Mai, A., Cheng, D., Bedford, M. T., Valente, S., Nebbioso, A., Perrone, A., Brosch, G., Sbardella, G., De Bellis, F., Miceli, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701595q · Cited by 135
Lee, W., Chen, H. H. W., Chow, N.-H., Su, W., Lin, P.-W., & Guo, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1761 · Cited by 135
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
deFazio, A., Chiew, Y.-E., Sini, R. L., Janes, P. W., & Sutherland, R. L. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4<487::aid-ijc5>3.0.co;2-j · Cited by 134
Xie, Y., & Hung, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2368 · Cited by 134
Self-citationLocalization of epidermal growth factor receptor in hepatocyte nuclei
Marti, U., Burwen, S. J., Wells, A. H., Barker, M. E., Huling, S. L., Feren, A. M., & Jones, A. L. (1991) · Hepatology · doi:10.1002/hep.1840130104 · Cited by 129
Tan, M., Jing, T., Lan, K., Neal, C. L., Li, P., Lee, S., Fang, D., Nagata, Y., Liu, J., Arlinghaus, R. B., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00510-5 · Cited by 128
Self-citationMinuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Mortenson, E. D., Radkevich-Brown, O., Wang, Y., & Fu, Y.-X. (2013) · Molecular Therapy · doi:10.1038/mt.2012.184 · Cited by 123
RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus
Huo, L., Wang, Y., Xia, W., Hsu, S.-C., Lai, C., Li, L., Chang, W., Wang, Y., Hsu, M., Yu, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000743107 · Cited by 118
Self-citationTissue transglutaminase-mediated chemoresistance in cancer cells
Verma, A., & Mehta, K. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.06.002 · Cited by 113
Thirumurthi, U., Shen, J., Xia, W., LaBaff, A. M., Wei, Y., Li, C.-W., Chang, W.-C., Chen, C.-H., Lin, H.-K., Yu, D., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005076 · Cited by 111
Self-citationBéguelin, W., Díaz Flaqué, M. C., Proietti, C. J., Cayrol, F., Rivas, M. A., Tkach, M., Rosemblit, C., Tocci, J. M., Charreau, E. H., Schillaci, R., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00012-10 · Cited by 110
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases
Chen, M., & Hung, M. (2015) · FEBS Journal · doi:10.1111/febs.13342 · Cited by 108
Self-citationThe status and role of ErbB receptors in human cancer
Überall, I., Kolář, Z., Trojanec, R., Berkovcová, J., & Hajdúch, M. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.12.002 · Cited by 107
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Murray, P. B., Lax, I., Reshetnyak, A. V., Ligon, G. F., Lillquist, J. S., Natoli, E. J., Shi, X., Folta‐Stogniew, E. J., Günel, M., Alvarado, D., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005916 · Cited by 106
Kim, Y. J., Choi, J., Seo, J., Song, J., Lee, S. E., Kwon, M. J., Kwon, M. J., Kundu, J., Jung, K., Oh, E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28566 · Cited by 102
Nuclear IGF1R is a transcriptional co‐activator of LEF1/TCF
Warsito, D., Sjöström, S., Andersson, S., Larsson, O., & Sehat, B. (2012) · EMBO Reports · doi:10.1038/embor.2011.251 · Cited by 100
Minireview: Were the IGF Signaling Inhibitors All Bad?
Beckwith, H. C., & Yee, D. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1157 · Cited by 94
Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis
Hadžisejdić, I., Mustać, E., Jonjić, N., Petković, M., & Grahovac, B. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.166 · Cited by 92
Activating ERBB4 mutations in non-small cell lung cancer
Kurppa, K. J., Denessiouk, K. A., Johnson, M. S., & Elenius, K. (2015) · Oncogene · doi:10.1038/onc.2015.185 · Cited by 90
Garrett, J. T., Sutton, C. R., Kurupi, R., Bialucha, C. U., Ettenberg, S. A., Collins, S. D., Sheng, Q., Wallweber, J., DeFazio-Eli, L., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1191 · Cited by 89
Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer
Hsu, Y.-H., Yao, J., Chan, L.-C., Wu, T.-J., Hsu, J. L., Fang, Y., Wei, Y., Wu, Y., Huang, W.-C., Liu, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0584 · Cited by 85
Self-citationDittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Kehlbach, R., & Rodemann, H. P. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.08.005 · Cited by 84
Chen, Y., Huang, W., Wei, Y.-L., Hsu, S.-C., Yuan, P., Lin, H. Y., Wistuba, I. I., Lee, J. J., Yen, C.-J., Su, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021428 · Cited by 84
Self-citationCanfield, K., Li, J., Wilkins, O. M., Morrison, M. M., Ung, M. H., Wells, W. A., Williams, C. R., Liby, K. T., Vullhorst, D., Buonanno, A., et al. (2015) · Cell Cycle · doi:10.4161/15384101.2014.994966 · Cited by 84
Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain
Thompson, M., Lauderdale, S., Webster, M. J., Chong, V. Z., McClintock, B., Saunders, R. C., & Weickert, C. S. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.047 · Cited by 79
Huang, L., Xu, A., & Liu, W. (2015) · Europe PMC (PubMed Central) · Cited by 77
Burga, L. N., Hu, H., Juvekar, A., Tung, N., Troyan, S. L., Hofstatter, E. W., & Wulf, G. M. (2011) · Breast Cancer Research · doi:10.1186/bcr2850 · Cited by 75
HER3/ErbB3, an emerging cancer therapeutic target
Zhang, N., Chang, Y., Rios, A., & An, Z. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv103 · Cited by 74
Bodzin, A. S., Wei, Z., Hurtt, R., Gu, T., & Doria, C. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.23041 · Cited by 72
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
Morrison, M. M., Hutchinson, K. E., Williams, M. M., Stanford, J. C., Balko, J. M., Young, C. D., Kuba, M. G., Sanchez, V. M., Williams, A. J., Hicks, D. J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66764 · Cited by 69
Naresh, A., Thor, A. D., Edgerton, S. M., Torkko, K. C., Kumar, R., & Jones, F. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0538 · Cited by 65
ErbB-4 s80 Intracellular Domain Abrogates ETO2-dependent Transcriptional Repression
Linggi, B., & Carpenter, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603998200 · Cited by 64
Met, the Hepatocyte Growth Factor Receptor, Localizes to the Nucleus in Cells at Low Density
Pozner-Moulis, S., Pappas, D. J., & Rimm, D. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4335 · Cited by 61
Fitz, C. D. V., Jensen, K. C., Nitta, R. T., Shain, A. H., Giacomini, C. P., & Wong, A. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2656 · Cited by 61
Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma
Gilbertson, R., Hernan, R., Pietsch, T., Pinto, L., Scotting, P., Allibone, R., Ellison, D., Perry, R., Pearson, A., & Lunec, J. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1146 · Cited by 60
HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival
Chiu, C. G., Masoudi, H., Leung, S. C. Y., Voduc, D. K., Gilks, C. B., Huntsman, D. D., & Wiseman, S. M. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181dbb77e · Cited by 60
Presence of anaplastic lymphoma kinase in inflammatory breast cancer
Robertson, F. M., Petricoin, E. F., Laere, S. V., Bertucci, F., Chu, K., Fernandez, S. V., Mu, Z., Alpaugh, K. R., Pei, J., Circo, R., et al. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-497 · Cited by 58
Secretase-dependent Tyrosine Phosphorylation of Mdm2 by the ErbB-4 Intracellular Domain Fragment
Arasada, R. R., & Carpenter, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506057200 · Cited by 57
Non-canonical signaling mode of the epidermal growth factor receptor family.
Lee, H., Wang, Y., & Hung, M. (2015) · Europe PMC (PubMed Central) · Cited by 57
Self-citationLinear combinations of docking affinities explain quantitative differences in RTK signaling
Gordus, A. G., Krall, J. A., Beyer, E. M., Kaushansky, A., Wolf‐Yadlin, A., Sevecka, M., Chang, B. H., Rush, A. J., & MacBeath, G. (2009) · Molecular Systems Biology · doi:10.1038/msb.2008.72 · Cited by 54
ALK alteration is a frequent event in aggressive breast cancers
Siraj, A. K., Beg, S., Jehan, Z., Prabhakaran, S., Ahmed, M., Hussain, A. R., Al‐Dayel, F., Tulbah, A. M., Ajarim, D. S., & Al-Kuraya, K. S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0610-3 · Cited by 53
Revelations of the RYK receptor
Halford, M. M., & Stacker, S. A. (2000) · BioEssays · doi:10.1002/1521-1878(200101)23:1<34::aid-bies1005>3.0.co;2-d · Cited by 52
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
Schillaci, R., Guzmán, P., Cayrol, F., Béguelin, W., Flaqué, M. C. D., Proietti, C. J., Pineda, V., Palazzi, J., Frahm, I., Charreau, E. H., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-74 · Cited by 51
Zhong, J., Kim, H.-T., Lyu, J., Yoshikawa, K., Nakafuku, M., & Lu, W. (2011) · Development · doi:10.1242/dev.061051 · Cited by 46
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Kim, J.-Y., Jung, H. H., Do, I.-G., Bae, S., Lee, S. K., Kim, S. W., Lee, J. E., Nam, S. J., Ahn, J. S., Park, Y. H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2195-3 · Cited by 44
ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas
Jeong, E. G., Soung, Y. H., Lee, J. W., Lee, S. H., Nam, S. W., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22257 · Cited by 42
Mill, C. P., Zordan, M. D., Rothenberg, S. M., Settleman, J., Leary, J. F., & Riese, D. J. (2011) · Genes & Cancer · doi:10.1177/1947601911431080 · Cited by 41
Psyrri, A. K., Egleston, B. L., Pectasides, E., Weinberger, P., Yu, Z., Kowalski, D. P., Sasaki, C. T., Haffty, B. G., Rimm, D. L., & Burtness, B. A. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2684 · Cited by 40
Cheng, C.-J., Ye, X.-C., Vakar‐Lopez, F., Kim, J., Tu, S., Chen, D., Navone, N. M., Yu‐Lee, L., Lin, S.-H., & Hu, M. C. ‐. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0306 · Cited by 38
Cdc37 Regulates Ryk Signaling by Stabilizing the Cleaved Ryk Intracellular Domain
Lyu, J., Wesselschmidt, R. L., & Lu, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900207200 · Cited by 36
Saldana, S. M., Lee, H., Lowery, F. J., Khotskaya, Y. B., Xia, W., Zhang, C., Chang, S.-S., Chou, C., Steeg, P. S., Yu, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073406 · Cited by 36
Self-citationROS1 Expression in Invasive Ductal Carcinoma of the Breast Related to Proliferation Activity
Eom, M., Lkhagvadorj, S., Oh, S., Han, A., & Park, K. H. (2013) · Yonsei Medical Journal · doi:10.3349/ymj.2013.54.3.650 · Cited by 32
Successes, toxicities and challenges in solid tumours
Neal, J. W., & Sledge, G. W. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.171 · Cited by 30
Xiong, Q., Chan, J. L. ‐., Zong, C. S., & Wang, L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1509 · Cited by 30
Warsito, D., Lin, Y., Gnirck, A.-C., Sehat, B., & Larsson, O. (2016) · Oncotarget · doi:10.18632/oncotarget.9785 · Cited by 30
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Wagner, J., Rapsomaniki, M. A., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 790
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A.-E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010130 · Cited by 398
Metadata
- Authors
- Hsu, J. L., & Hung, M.-C.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2016-12
- Volume
- 35
- Issue
- 4
- Pages
- 575-588
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2557509406
- Cited by
- 445
- References
- 204
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.